Alert
Upgrade to PRO+
PRO+ subscribers get unlimited access to EMARKETER charts and data. Utilize our vast library of charts to validate strategic ideas and establish thought leadership via internal and external presentations.
Upgrade to PRO+
PRO+ subscribers get unlimited access to EMARKETER charts and data. Utilize our vast library of charts to validate strategic ideas and establish thought leadership via internal and external presentations.
Request successfully sent
Thank you. A member of our team will reach out shortly.
If you need immediate assistance, email us at sales@emarketer.com
October 19, 2021
Leading Barriers to Prescription Digital Therapeutics (PDTs) Adoption According to US Payers and Employers, Summer 2021 (% of respondents)
Methodology
Data is from the October 2021 Pear Therapeutics and Avalere report titled, "Pear Prescription Digital Therapeutics (PDT) Digest." 40 US payers (n=30) and employers (n=10), who are familiar with PDT, were surveyed during summer 2021. 75% of the respondents was payer or pharmacy benefit managers, and 25% was employer or employer benefits consultants who represented employer self-insured groups. The payer respondents collectively represented 192 million covered lives.Featured In
Pear Therapeutics launches new program to improve digital patient access to addiction treatment Pfizer, Moderna drop off in consumer ranking of favorite brands—that could stymie uptake of their digital therapiesResMed acquires mementor to grow its sleep app lineupDigital health startups to watch: LetsGetChecked raises $20M from JPMorgan Chase, Otolith Labs scores $20M for vertigo wearableChart Title
Leading Barriers to Prescription Digital Therapeutics (PDTs) Adoption According to US Payers and Employers, Summer 2021 (% of respondents)Publication Date
October 19, 2021